Skip to main content
Premium Trial:

Request an Annual Quote

Natera, UCSF Partner to Study DNA Biomarkers of Kidney Transplant Rejection

NEW YORK (GenomeWeb) – Natera announced today that it has formed a collaboration with the University of California, San Francisco to study DNA markers of kidney transplant rejection.

Under the terms of the arrangement, Natera will use its proprietary massively multiplexed PCR platform and algorithms to analyze the level of donor-derived cell-free DNA (dd-cfDNA) in hundreds of retrospectively banked plasma samples collected at UCSF from kidney transplant recipients both with and without organ injury. The partners aim to establish whether dd-cfDNA can be used to predict organ injury in kidney transplantation and improve clinical outcomes.

Additional terms of the partnership were not disclosed.

"It is still very difficult to detect quickly whether an individual patient is recovering well or rejecting the organ," UCSF's Minnie Sarwal, who is working with Natera on the project, said in a statement. "Because the speed of that detection is crucial in preventing acute rejection, our goal is to develop a test that will help us identify which patients are at greatest risk before the damage is irreversible."

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.